Adamas announces final results from two-year phase 3 open-label study of GOCOVRI™ in PD
Adamas Pharmaceuticals announced positive data from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, the first and only medicine approved by the FDA for treatment of dyskinesia in patients with Parkinson's disease. April 19, 2018